Drug Channels

MARCH 15, 2022

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

Specialty Pharmacies 98

Specialty Pharmacies Pharmaceutical Manufacturing Drug Pricing Documentation 98

Proxsys Rx

OCTOBER 24, 2022

What’s more, according to Acentrus Specialty , a specialty pharmacy consulting firm, 8 out of 10 new drugs approved by the FDA in 2020 were specialty drugs. In short, specialty drugs constitute the fastest-growing and largest part of the prescription-drug market.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Pharmaceutical Manufacturing 52

Drug Channels

MARCH 18, 2025

Weve updated all market and industry data with the most current insights, including our annual analyses of the largest pharmacies, specialty pharmacies, and PBMs. WHATS GOING ON Twice a year, the DCI team researches and writes two comprehensive, fact-based, and nonpartisan reports on drug channel economics.

Specialty Pharmacies 52

Specialty Pharmacies Pharmaceutical Manufacturing Drug Pricing Hospitals 52

Pharmaceutical Commerce

JUNE 18, 2025

Asembia’s AXS25 Summit—held annually at both the Wynn and Encore in Las Vegas, NV—brings together thousands of pharmaceutical industry executives in hopes of continuing the conversation surrounding specialty pharmacy.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Pharmacy Technician Pharmaceutical Companies 52

Pharmacy Times

JUNE 4, 2025

The Advanced Technologies Lab will help industry and regulators accelerate the adoption of new technologies that help to mitigate supply chain risks and, where appropriate, establish guidance that supports regulatory predictability, process efficiencies, and faster time to market, all of which can strengthen domestic manufacturing capabilities.

Pharmaceutical Manufacturing 26

Pharmaceutical Manufacturing Pharmacy Technician Compounding Pharmacies Compounding 26

Ramblings of a pharmacist

DECEMBER 27, 2024

We can also see from this excerpt that at the scale of large PBMs, formulary strategies are also a piece of negotiating leverage to obtain rebates and fees from pharmaceutical manufacturers. However, once negotiations are completed and rebate contracted executed, rebates can be cut off punitively by pharmaceutical manufacturers.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Specialty Pharmacies Documentation Hospitals 98

Pharmaceutical Commerce

JUNE 18, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Specialty Pharmacies Drug Pricing Pharmaceutical Manufacturing 52

Pharmacy Times

JUNE 8, 2025

Within this expansive network, the neurology clinical pharmacy specialist serves a vital dual role. The position ensures continuous care coordination and medication oversight across the system’s specialty pharmacy and neurology practices. Presented at: American Society of Health-System Pharmacists 2025 Pharmacy Futures.

Pharmacy Technician 29

Pharmacy Technician Specialty Pharmacies Communication Immunity 29

Pharmacy Times

JUNE 23, 2025

For submission consideration, manufacturers can petition the FDA for ANDA status if the requested change does not require safety or effectiveness studies. It is basically an essential copy, and the pharmaceutical manufacturer has to show bioequivalence to the reference product,” Soefje said. “If

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Drug Channels

OCTOBER 10, 2023

reviews the evolving specialty pharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. The notable new material in this 2023-24 edition includes: New data about commercial pricing and reimbursement for provider-administered biosimilars appears in Section 3.2.2.

Specialty Pharmacies 40

Specialty Pharmacies Biosimilars Pharmaceutical Manufacturing Documentation 40

Pharmaceutical Commerce

JUNE 18, 2025

Download Issue PDF Articles in this issue Pharmaceutical Commerce: June 2025 Interactive Digital Edition The Art of Agility DSCSA Compliance: The Time is Now Conference Connect: Determining the Future of Specialty Pharmacy Bolstering Health Technology Assessment With the Help of AI Changing the PAP Model Building Intelligent Pharma Supply Chain Management (..)

Drug Pricing 52

Drug Pricing Specialty Pharmacies Pharmaceutical Manufacturing Documentation 52

Pharmacy Times

JUNE 12, 2025

5 The Most Significant Driver of Health Care Spend Isn’t Drugs—It Isn’t Even Close Pharmaceutical manufacturers are a frequent punching bag for politicians, mostly because they are easy targets, and they tend to have more visible out-of-pocket exposure.

Pharmacy Technician 26

Pharmacy Technician Community Pharmacies Drug Pricing Hospitals 26

Pharmacy Times

JUNE 16, 2025

3,4 How this pricing model will be implemented and whether pharmaceutical manufacturers will be able to meet the expectations of the 2025 executive order, if upheld, is uncertain. The order states that if manufacturers are unable to meet the 30-day deadline, the secretary of the Department of Health and Human Services, Robert F.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26